U.S. markets closed
  • S&P 500

    4,204.31
    -55.21 (-1.30%)
     
  • Dow 30

    32,944.19
    -229.88 (-0.69%)
     
  • Nasdaq

    12,843.81
    -286.16 (-2.18%)
     
  • Russell 2000

    1,979.67
    -32.00 (-1.59%)
     
  • Crude Oil

    109.09
    +3.07 (+2.90%)
     
  • Gold

    1,992.30
    -8.10 (-0.40%)
     
  • Silver

    26.22
    -0.04 (-0.14%)
     
  • EUR/USD

    1.0915
    -0.0079 (-0.72%)
     
  • 10-Yr Bond

    2.0040
    -0.0070 (-0.35%)
     
  • GBP/USD

    1.3038
    -0.0045 (-0.34%)
     
  • USD/JPY

    117.2800
    +1.1500 (+0.99%)
     
  • BTC-USD

    39,162.80
    +68.73 (+0.18%)
     
  • CMC Crypto 200

    871.90
    +7.96 (+0.92%)
     
  • FTSE 100

    7,155.64
    +56.55 (+0.80%)
     
  • Nikkei 225

    25,162.78
    -527.62 (-2.05%)
     

Summit Therapeutics' Infection Candidate Flunks In Head-To-Head Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Summit Therapeutics Inc (NASDAQ: SMMT) shares are trading lower after disappointing results from the Phase 3 Ri-CoDIFy study of ridinilazole for C. difficile infection (CDI).

  • The study showed that ridinilazole resulted in a higher observed Sustained Clinical Response (SCR) rate than vancomycin but did not meet the study's primary endpoint for superiority.

  • Patients treated with ridinilazole, a precision antibiotic, experienced substantially less recurrence of C. diff. Infection as compared to patients administered vancomycin.

  • Related: FDA Not In Favor Of Summit Therapeutics' Endpoint Change To Pivotal Infection Trials.

  • Full results from the Ri-CoDIFy study will be presented at upcoming medical conferences and published in a peer-reviewed medical journal.

  • The Company will continue to evaluate the underlying data and perform additional analyses, including analyses specific to the microbiome.

  • The Company is also announcing that it anticipates commencing rights offering in January 2022.

  • It is expected that the record date for the distribution of rights will be in mid-January.

  • Price Action: SMMT shares are down 46.4% at $2.67 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.